GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
Open original source
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
Open original source